These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 30557739)

  • 21. The impact of depression and antidepressant usage on primary biliary cholangitis clinical outcomes.
    Shaheen AA; Kaplan GG; Almishri W; Vallerand I; Frolkis AD; Patten S; Swain MG
    PLoS One; 2018; 13(4):e0194839. PubMed ID: 29617396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between pruritus and sleep in participants with primary biliary cholangitis in the Phase 2b GLIMMER trial.
    von Maltzahn R; Mayo MJ; Smith HT; Thompson A; Das S; de Souza AR; Lisi E; Levy C; McLaughlin MM; Jones D
    J Patient Rep Outcomes; 2024 Jun; 8(1):60. PubMed ID: 38862718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Update on the Treatment and Follow-up of Patients with Primary Biliary Cholangitis.
    Burman BE; Jhaveri MA; Kowdley KV
    Clin Liver Dis; 2017 Nov; 21(4):709-723. PubMed ID: 28987258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disease burden of primary biliary cholangitis and associated pruritus based on a cross-sectional US claims analysis.
    Gungabissoon U; Gibbons DC; Requena G; Ribeiro de Souza A; Smith H
    BMJ Open Gastroenterol; 2022 Aug; 9(1):. PubMed ID: 35973742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
    Bowlus CL; Galambos MR; Aspinall RJ; Hirschfield GM; Jones DEJ; Dörffel Y; Gordon SC; Harrison SA; Kremer AE; Mayo MJ; Thuluvath PJ; Levy C; Swain MG; Neff GW; Sheridan DA; Stanca CM; Berg CP; Goel A; Shiffman ML; Vierling JM; Boudes P; Steinberg A; Choi YJ; McWherter CA
    J Hepatol; 2022 Aug; 77(2):353-364. PubMed ID: 35367282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigational drugs in phase II clinical trials for primary biliary cholangitis.
    Silveira MG; Lindor KD
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1115-1121. PubMed ID: 28836457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase.
    Murillo Perez CF; Harms MH; Lindor KD; van Buuren HR; Hirschfield GM; Corpechot C; van der Meer AJ; Feld JJ; Gulamhusein A; Lammers WJ; Ponsioen CY; Carbone M; Mason AL; Mayo MJ; Invernizzi P; Battezzati PM; Floreani A; Lleo A; Nevens F; Kowdley KV; Bruns T; Dalekos GN; Gatselis NK; Thorburn D; Trivedi PJ; Verhelst X; Parés A; Janssen HLA; Hansen BE;
    Am J Gastroenterol; 2020 Jul; 115(7):1066-1074. PubMed ID: 32618657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toward precision medicine in primary biliary cholangitis.
    Carbone M; Ronca V; Bruno S; Invernizzi P; Mells GF
    Dig Liver Dis; 2016 Aug; 48(8):843-50. PubMed ID: 27324985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
    Yuan Z; Jia G; Han Y
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concomitant Sjögren's Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis.
    Ni P; Men R; Shen M; Wang T; Huang C; Fan X; Yang L
    Can J Gastroenterol Hepatol; 2019; 2019():7396870. PubMed ID: 31275901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current Status of Liver Transplantation for Primary Biliary Cholangitis.
    Aguilar MT; Carey EJ
    Clin Liver Dis; 2018 Aug; 22(3):613-624. PubMed ID: 30259857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis.
    Mayo MJ; Carey E; Smith HT; Mospan AR; McLaughlin M; Thompson A; Morris HL; Sandefur R; Kim WR; Bowlus C; ; Levy C
    Dig Dis Sci; 2023 Mar; 68(3):995-1005. PubMed ID: 35704252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cholestatic Pruritus Treatments in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Systematic Literature Review.
    Smith HT; de Souza AR; Thompson AH; McLaughlin MM; Dever JJ; Myers JA; Chen JV
    Dig Dis Sci; 2023 Jun; 68(6):2710-2730. PubMed ID: 36933112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RANK/RANKL Acts as a Protective Factor by Targeting Cholangiocytes in Primary Biliary Cholangitis.
    Hao YL; Bian ZL; Ju LL; Liu Y; Qin G
    Dig Dis Sci; 2020 Feb; 65(2):470-479. PubMed ID: 31377883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidemiology and clinical course of primary biliary cholangitis in Eastern Slovakia.
    Drazilova S; Babinska I; Gazda J; Halanova M; Janicko M; Kucinsky B; Safcak D; Martinkova D; Tarbajova L; Cekanova A; Jarcuska P;
    Int J Public Health; 2020 Jun; 65(5):683-691. PubMed ID: 32500239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cholestatic liver diseases].
    Thimme R; Opitz OG; Blum HE; Kreisel W
    Ther Umsch; 2004 Aug; 61(8):521-7. PubMed ID: 15457969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natural history of pruritus in primary biliary cirrhosis.
    Talwalkar JA; Souto E; Jorgensen RA; Lindor KD
    Clin Gastroenterol Hepatol; 2003 Jul; 1(4):297-302. PubMed ID: 15017671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patients.
    Weinmann A; Sattler T; Unold HP; Grambihler A; Teufel A; Koch S; Schuchmann M; Biesterfeld S; Wörns MA; Galle PR; Schulze-Bergkamen H
    J Clin Gastroenterol; 2015; 49(5):438-47. PubMed ID: 25014239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.
    Lammers WJ; Hirschfield GM; Corpechot C; Nevens F; Lindor KD; Janssen HL; Floreani A; Ponsioen CY; Mayo MJ; Invernizzi P; Battezzati PM; Parés A; Burroughs AK; Mason AL; Kowdley KV; Kumagi T; Harms MH; Trivedi PJ; Poupon R; Cheung A; Lleo A; Caballeria L; Hansen BE; van Buuren HR;
    Gastroenterology; 2015 Dec; 149(7):1804-1812.e4. PubMed ID: 26261009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk stratification and prognostic modelling in primary biliary cholangitis.
    Goet JC; Harms MH; Carbone M; Hansen BE
    Best Pract Res Clin Gastroenterol; 2018; 34-35():95-106. PubMed ID: 30343715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.